| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 25 Mar 2025 | 25 Mar 2025 |
| The Board of Directors of the Company at their meeting held on 25-03-2025 has interalia considered and approved the following: Reappointment of M/s. Joshi Apte & Associates, Cost Accountants, as the Cost Auditors of the Company for the financial year 2025-2026 | ||
| Board Meeting | 21 Jan 2025 | 13 Jan 2025 |
| INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/01/2025 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended 31-12-2024 Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 21st January, 2025 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2024 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2024 (As per BSE Announcement Dated on 21/01/2025) | ||
| Board Meeting | 24 Oct 2024 | 14 Oct 2024 |
| INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/10/2024 inter alia to consider and approve The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended 30-09-2024 Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 24th October, 2024 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September, 2024 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. Read less.. Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September, 2024 (As Per BSE Announcement Dated on 24.10.2024) | ||
| Board Meeting | 23 Jul 2024 | 10 Jul 2024 |
| INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2024 inter alia to consider and approve the Unaudited Standalone & Consolidated Financial Results of the Company for the quarter ended 30-06-2024 Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 23rd July, 2024 has inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2024 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. (As per BSE Announcement Dated on 23/07/2024) | ||
| Board Meeting | 16 May 2024 | 8 May 2024 |
| INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2024 inter alia to consider and approve 1. The Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended 31st March 2024. 2. To recommend a final dividend if any for the financial year ending 31st March 2024. Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 (Listing Regulations), we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 16th May, 2024 has inter-alia considered and approved the following. 1. Audited Financial Results (Consolidated and Standalone) for the quarter and year ended 31st March, 2024 and Auditors Reports with unmodified opinions on the aforesaid Audited Financial Results. 2. Subject to the approval of the Members at the ensuing 77th Annual General Meeting, recommended a Dividend of Rs. 1.50 per equity share on face value of Rs. 2/- for the financial year 2023-2024 Approval of Standalone and Consolidated Financial Results for the Quarter and Year ended 31st March, 2024 (As per BSE Announcement Dated on 16/05/2024) | ||
Indoco Remedies stated that it will respond to the Form 483 observations within the prescribed timeline.
Here are some of the stocks that may see significant price movement today: IndusInd Bank, Hindustan Zinc, Thermax, etc.
Indoco Remedies will also continue providing products to its existing B2B customers under existing deals.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
